case_images: PMC8767018_01
case_images: PMC8767018_02
case_images: PMC8767018_03
case_images: PMC8767018_04
case_images: PMC8767018_05
case_images: Observed values for Urinary Oxalate/creatinine ratio from the last measurement before lumasiran to Month 18. ULN denotes upper limit of the normal range.
case_images: fped-09-791616-g0001.jpg
case_images: PMC8767018_05_fped-09-791616-g0001.jpg
case_images: F1
case_images: The patient showed a rapid and sustained decrease in urinary oxalate/creatinine ratio (see Figure 1). During the 18 months follow-up period, urinary oxalate remained low reaching nearly normal values (see Figure 1).
case_images: Observed values for Plasma Oxalate from the last measurement before lumasiran to Month 18. ULN denotes upper limit of the normal range.
case_images: fped-09-791616-g0002.jpg
case_images: PMC8767018_05_fped-09-791616-g0002.jpg
case_images: F2
case_images: Normal plasma oxalate levels were reached immediately after the first dose and the values remained consistently low during the 18 months follow-up period (see Figure 2).
case_images: PMC8767018_06